Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.05−0.00 (-5.10%)
Close on Nov 20, 2026Market cap $1.09MP/E –Yield –
Vivos Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vivos Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$19.01M. For fiscal 2025 it was -$17.60M. The highest annual figure on record is -$5.52M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.60M | – |
| FY2024 | Dec 31, 2024 | -$13.26M | – |
| FY2023 | Dec 31, 2023 | -$12.75M | – |
| FY2022 | Dec 31, 2022 | -$20.51M | – |
| FY2021 | Dec 31, 2021 | -$18.13M | – |
| FY2020 | Dec 31, 2020 | -$5.80M | – |
| FY2019 | Dec 31, 2019 | -$5.52M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.34M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.11M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.94M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.50M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.71M | – |
| Q3 FY2020 | Sep 30, 2020 | -$686.45K | – |
| Q2 FY2020 | Jun 30, 2020 | -$958.40K | – |
| Q1 FY2020 | Mar 31, 2020 | -$442.11K | – |
See a number that looks wrong?